Systematic review uncovers the effects of COVID-19 control measures on dementia and carers, suggesting societal and health service implications.
<ns3:p>Background COVID-19 control measures have had a unique impact on people with dementia (PWD) and their carers living at home. Yet, uncertainty exists regarding the global impact of such measures, and whether differences exist between countries and global regions. We aimed to synthesize evidence on this topic. Methods We searched Medline, PsycINFO, EMBASE, Web of Science, CINAHL, Latin American and Caribbean Health Literature (Lilacs), Scientific Electronic Library online (Scielo), and EM Premium, from the start of the pandemic to July 2022. At least two researchers independently screened citations and performed quality assessment following recommended criteria for critical appraisal according to study methodology. We analyzed data by country and region, and synthesized results descriptively. Results Sixty-nine studies met inclusion criteria (74% qualitative and 26% quantitative; 22% included PWD, 44% carers of PWD, 4% dyads), with a total of 209,738 participants. Most studies were conducted in Europe (59%), followed by Asia and North America (15% each), South America (7%) and Oceania (1%). Two studies presented data from multiple regions (3%). The quality of the studies varied, with the majority (62%) being of moderate quality. Across the study populations and global regions, COVID-19 control measures had implications for PWD and carers’ access to health services, physical and mental health and daily routine, cognition, behaviour, with accompanying social and economic costs. Conclusion Our results highlight how public health measures impacted PWD and their carers living at home globally, and suggest the need for proactive planning of preventive measures to mitigate the negative impact, in anticipation of future public health threats. Other This work was funded by the JPND Call for Expert Working Groups: The Impact of COVID-19 on Neurodegenerative Diseases in partnership with the CIHR-Institute of Aging; Public Health Agency (CIHR #02342-000). PROSPERO CRD42024554701.</ns3:p>
No takes yet. Share an insight, caveat, or question.
Chen et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: